Antibiotic Treatment of GNR MDR Infections. Stan Deresinski
|
|
- Clement Flowers
- 5 years ago
- Views:
Transcription
1 Antibiotic Treatment of GNR MDR Infections Stan Deresinski
2 Kucers: The Use of Antibiotics 1st Edition pages
3 Kucers: The Use of Antibiotics 7 th Edition pages
4
5 Carbapenem Susceptibility SHC 2016 % SUSCEPTIBLE K. pneumoniae E. coli E. aerogenes E. cloacae Imipenem Meropenem Ertapenem
6
7
8 Mechanisms of Carbapenem Resistance Carbapenemases e.g., bla KPC, bla NDM, bla VIM, bla OXA-48, and bla IMP Porin alterations decreased OM permeability Efflux upregulation Hyperproduction of ESBLs, AmpC in combination with porin, efflux mutations Altered penicillin-binding proteins
9 Rx CRE pre-2015 Polymyxin B/Colistin Tigecycline Best results: combination of one in vitro active drug with optimally dosed/administered anti-pseudomonal carbapenem. Robilotti, Deresinski F1000Rep 2014; 6:80. Watkins, Deresinski Exp Review Anti Infect Ther 2015; 13:405-7.
10 COLISTIN (POLYMYXIN E)
11 Polymyxins Resistance Mechanisms Polymyxins are polycationic at physiologic ph and depend on binding to negatively charged outer layer of outer bacterial cell membrane Resistance primarily due to post-translational modification of OM LPS reducing net negative charge of phosphate residues (ie, making it more +) Most often: addition of, eg, phosphonoethanolamine to lipid A of LPS core Mutational or acquisition of mcr (plasmid-mediated) In some cases, complete loss of LPS Int J Antimicrob Agents 2017; 49:
12 Colistin (Polymyxin E) Multiple components; may be batchbatch variation Administered as inactive prodrug: Na+ salt of colistin methanesulfonate (CMS; colistemethate) Renal clearance of CMS (converted in urine) more efficient than conversion to parent Conversion is slow (hours to therapeutic) and incomplete (approx. 25%) Significant inter-pt clearance variability Nephrotoxic Uses: UTI, Inhalational Polymyxin B Multiple components Active moiety (as sulfate salt) Mainly non-renal excretion dosage adjustments not required Nephrotoxic Uses: Non-UTI
13
14 Colistimethate Slow hydrolysis to active Form 4 hours required to reach peak colistin concentration - But below breakpoint
15 TIGECYCLINE: 9-t-butylglycyclyl minocycline 9-t-butylglycyclyl amido side chain: Enables binding to 30s RNA even in presence of Tet(M) Makes tigecycline a poor substrate for tetracycline-specific efflux pumps
16 Tigecycline Intrinsic Resistance Constitutive overexpression of multidrug efflux pumps (e.g., AcrB) Pseudomonas aeruginosa Proteus spp. Providencia spp. Some Morganella morganii Clin Infect Dis 2006; 43:
17
18 Treatment of Bacteremia Due to KPC-Producing K. pneumoniae Combination Rx (n=103) Monotherapy (n=72) Survival with Combination Rx Include a carbapenem (n=31) 80.7% No carbapenem (n=72) 69.4% Daikos et al. AAC 2014; 58:
19 Prospective Randomized Trial Rx of Severe Carbapenem- Resistant Gram Negative Infections (Mostly A. baumanii) 312/406 Acinetobacter baumanii Colistin +/- meropenem Overall, no significant difference between mono- or combo-therapy for clinical failure Acinetobacter also no significant difference between mono- or combo-therapy Lancet ID 2018 Published Online February 15,
20
21 MEROPENEM PHARMACODYNAMIC TARGET ATTAINMENT MEROPENE Enterobacteriaceae Susc: <1 mcg/ml Inter: 2 Resist: >4 Clin Microbiol Infect. 2011; 17:
22 MEROPENEM PHARMACODYNAMIC TARGET ATTAINMENT MEROPENE Enterobacteriaceae Susc: <1 mcg/ml Inter: 2 Resist: >4 Clin Microbiol Infect. 2011; 17:
23 MEROPENEM PHARMACODYNAMIC TARGET ATTAINMENT MEROPENE Enterobacteriaceae Susc: <1 mcg/ml Inter: 2 Resist: >4 Clin Microbiol Infect. 2011; 17:
24 MEROPENEM PHARMACODYNAMIC TARGET ATTAINMENT Enterobacteriaceae Susc: <1 mcg/ml Inter: 2 Resist: >4 MEROPENE Enterobacteriaceae Susc: <1 mcg/ml Inter: 2 Resist: >4 Clin Microbiol Infect. 2011; 17:
25 Altered Antibody PK in Sepsis J Intens Care Soc
26 Prolonged versus short-term intravenous infusion of antipseudomonal β-lactams for patients with sepsis: a systematic review and meta-analysis of randomised trials Lancet ID 2018; 18:108-20
27
28 Avibactam active against: Class A & C (including AmpC, ESBLs, KPC) and some OXA (Class D). Not Class B (MLBs)
29 Ceftazidime Avibactam (CAv) IAI: CAv + metronidazole non-inferior to meropenem 1 cuti: CAv vs. imipenem/cilastatin cuti: (RECAPTURE) CAv non-inferior to doripenem cuti due to ceftazidime non-susceptible isolates: (REPRISE) CAv superior to best available Rx: 70.1% vs 50.4% ( 16.1%; 95% CI 4.8 TO 27.1) HAP/VAP: (REPROVE) 1. Clin Infect Dis 2016; 62:
30 REPROVE: Ceftazidime/Avibactam Non- Inferior to Meropenem in HAP/VAP 808 evaluable patients Micro population: 37% of K. pneumoniae, 30% P. aeruginosa 28% ceftazidime non-susceptible Clinically modified intent-to-treat (ITT) Clinical cure in 245 (68.6%) of 356 CAv recipients & 270 (73.0%) of 370 meropenem (difference 4 2% [95% CI 10 8 to 2 5]) Clinically evaluable population Clinical cure in 199 (77.4%) of 257 CAv and 211 (78.1%) of 270 meropenem recipients (difference 0 7% [95% CI 7 9 to 6 4]) Lancet Infect Dis Dec 15. pii: S (17) doi: /S (17)
31 Ceftazidime/Avibactam Vs. Alternative Therapies for Carbapenem-Resistant K. pneumoniae Bacteremia Retrospective Analysis U. Pittsburgh 30-Day Clinical Success Survival Resolution S&S BC negative <7 d No recurrence 106/109 (97%) KPC Shields et al. Antimicrob. Agents Chemother. 2017;61:e
32 % Susceptible 120 P. aeruginosa SHC P/T Cefepime Aztreonam Mero Tobra Cipro P aeruginosa CF-Mucoid CF-Non-Mucoid P aeruginosa (Total) N = 545 CF-Mucoid N = 130 CF-Non-Mucoid. N = 101
33 Ceftolozane/Tazobactam: A Novel Cephalosporin/β Lactamase Inhibitor Combination Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy Volume 35, Issue 7, pages , 1 JUL 2015 DOI: /phar
34 Antimicrob. Agents Chemother.January 2018 vol. 62 no. 1
35 The Inevitable Emergence of Resistance Ceftazidime/ avibactam - Initial FDA Approval Feb 2015 Rx CRE: 3/10 microbiological failures developed resistance Resistance due to mutations in blakpc3 (but restored carbapenem susceptibility in some isolates). Ceftolozane/tazobactam Initial FDA Approval Dec 2014 Rx MDR PA: 3/21 developed resistance ampc overexpression and structural mutations Clin Infect Dis Dec 15;63(12): ; AAC Mar; 61(3): e AAC 2017 Feb 23;61(3). pii: e doi: /AAC
36 Meropenem/Vaborbactam FDA Approval - August 2017 Vaborbactam: non-bl/bli based on a cyclic boronic acid pharmacophore inhibits Class A and C β-lactamases, including Ambler Class A carbapenemases (eg, KPC) Does not inhibit Class B or D carbapenemases Increased expression of OmpK36 porin elevates MICs Major target KPC-producers
37 Meropenem-Vaborbactam & Enterobacteriaeceae Carrying KPC 991 clinical isolates KPC+, negative for OXA-48 & MBL MIC90: 1 mcg/ml (FDA breakpoint: 4 mcg/ml) Range: < >32 mcg/ml 99.0% (989/991) had MIC <4 mcg/ml
38 TANGO-2: Meropenem/Vaborbactam vs. Best Available Bacteremia, Pneumonia, cuti, IAI Stopped after 72 patients (43 CRE, 20 with bacteremia; 86% KP) by DSMB: risk-benefit analysis of available no longer supported randomization of additional patients to the best available therapy comparator arm Efficacy: Statistically significant differences favored meropenem/vaborbactam for clinical cure at TOC visit & mortality rates were also lower AEs: lower rates of renal events and serum creatinine increases particularly in patients receiving colistin and [sic] aminoglycosides
39 What About Infections with MBL-producing Organisms?
40
41 K. Pneumoniae NDM+ ESBL+ J Antimicrob Chemother. 2017;73(2): doi: /jac/dkx393
42 K. pneumoniae with NDM, OXA, CTX-M Rx with Aztreonam + Ceftazidime/Avibactam 10 patients infected with K. pneumoniae ST147 carrying NDM-1, OXA- 48, CTX-M MICs: aztreonam >32, ceftaz/avi >16/4 Clinical success (negative culture at 7 days + survival & no recurrence at 30 days): 6/10 3 deaths (none infection-related), 1 recurrence Journal of Antimicrobial Chemotherapy, dkx496,
43 % Susceptible A. baumanii SHC 2016 N = Amp/Sul Cefepime Meropenem Tobra Amikacin Cipro T/S Ceftazidime/Avibactam 321 Acinetobacter spp. MIC50/90: 16/> % susceptible (based on CLSI, ceftaz) AAC 2014; 58:
44 % Susceptible Achromobacter xylosidans SHC 2016 N = Ceftolozane/tazobactam 11/11 CF isolates resistant; 9/11 P/T resistant AAC 2017; 61:e
45 Some Antibiotics Active Against MDR GNR with Expected/Possible Approval Dates Eravacycline (Tetraphase) Plazomicin (Achaogen) Fosfomycin IV (Zavante) Cefiderocol (Shinogi)
46 Cefiderocol Siderophore cephalosporin Panel (N=315) of carbapenemaseproducing MDR GNR MIC <4 mcg/ml: Enterobacteriaeceae 87.5% P. aeruginosa - 100% A. baumanii - 89% Activity by carbapenemase type: A 91.8% B % D 98.0% IDWeek Abstract 1230
47 Cefiderocol (S )MDR GNR Meropenem Non-Susceptible CRE Acinetobacter baumanii N = 1022 N = 368 AAC 2018 Jan 25;62(2). pii: e doi: /AAC
48 Cefiderocol (S ) MDR GNR MDR Pseudomonas aeruginosa N = 262 Stenotrophomonas maltophilia N = 217 AAC 2018 Jan 25;62(2). pii: e doi: /AAC
49 Cefiderocol Vs. Imipenem/Cilastatin in Acute cuti +/- Pyelonephritis Or Acute Uncomplicated Pyelonephritis APEKS-cUTI Response at Test of Cure in Microbiological Intent-to-Treat Population Cefiderocol N (%) Imipenem/Cil N (%) Adjusted % 95% CI # Pts Clinical + Micro* 183 (72.6%) 65 (54.6%) 28.9% 8.23%, 28.92% Clinical 226 (89.7%) 104 (87.4%) 2.4% -4.66%, 9.44% *Primary endpoint Portsmouth et al. IDWeek Abstract 1869
50
51 An Alternative Approach: John Lettsome s Guideline If any sick applies to me, I bleeds, cups, and sweats em If they then should chance to die,
52 An Alternative Approach: John Lettsome s Guideline If any sick applies to me, I bleeds, cups, and sweats em If they then should chance to die, I, John Lettsome
Nightmare Bacteria. Disclosures. Technician Objectives. Pharmacist Objectives. Carbapenem Resistance in Carbapenem Resistance in 2017
Nightmare Bacteria How to Deal with the Reality of Carbapenem-resistant Organisms Disclosures I have no conflicts of interest relative to the content of this presentation Matthew L. Brown, Pharm.D., BCPS
More informationNew insights in antibiotic and antifungal therapy in the compromised host
New insights in antibiotic and antifungal therapy in the compromised host Claudio Viscoli University of Genova Ospedale Policlinico San Martino, Genova Potential conflicts of interest (last 5 years) Received
More informationFocusing on beta-lactams and beta-lactamase inhibitors
New and Emerging Antibiotics: Data and Practical Recommendations Focusing on beta-lactams and beta-lactamase inhibitors Robert A. Bonomo, M.D. Medical Service, Louis Stokes Cleveland VAMC Department of
More informationALERT. Clinical microbiology considerations related to the emergence of. New Delhi metallo beta lactamases (NDM 1) and Klebsiella
ALERT Clinical microbiology considerations related to the emergence of New Delhi metallo beta lactamases (NDM 1) and Klebsiella pneumoniae carbapenemases (KPC) amongst hospitalized patients in South Africa
More informationNONFERMENTING GRAM NEGATIVE RODS. April Abbott Deaconess Health System Evansville, IN
NONFERMENTING GRAM NEGATIVE RODS April Abbott Deaconess Health System Evansville, IN OBJECTIVES Discuss basic limitations to assessing carbapenem resistance in nonfermenting GNRs Discuss antimicrobial
More informationIn Vitro Activity of Ceftazidime-Avibactam Against Isolates. in a Phase 3 Open-label Clinical Trial for Complicated
AAC Accepted Manuscript Posted Online 21 November 2016 Antimicrob. Agents Chemother. doi:10.1128/aac.01820-16 Copyright 2016, American Society for Microbiology. All Rights Reserved. 1 2 3 4 5 6 7 8 9 10
More informationMechanisms of Resistance to Ceftazidime-Avibactam. Romney M. Humphries, PhD D(ABMM) Chief Scientific Officer Accelerate Diagnostics.
Mechanisms of Resistance to Ceftazidime-Avibactam Romney M. Humphries, PhD D(ABMM) Chief Scientific Officer Accelerate Diagnostics UCLA, January 2015 62 year old woman with advanced pancreatic cancer Vomiting
More informationA Snapshot of Colistin Use in South-East Europe and Particularly in Greece
A Snapshot of Colistin Use in South-East Europe and Particularly in Greece Helen Giamarellou 02.05.2013 When Greek Physicians Prescribe Colistin? It is mainly prescribed in the ICU for VAP, bacteremia
More informationXERAVATM (eravacycline): A Novel Fluorocycline Antibacterial
XERAVATM (eravacycline): A Novel Fluorocycline Antibacterial Matteo Bassetti, MD, PhD Infectious Diseases Division University of Udine and Santa Maria Misericordia University Hospital Udine, Italy Disclosures
More informationNew treatments of multidrug-resistant Gram-negative ventilatorassociated
Review Article Page 1 of 22 New treatments of multidrug-resistant Gram-negative ventilatorassociated pneumonia Garyphallia Poulakou 1, Styliani Lagou 1, Drosos E. Karageorgopoulos 2, George Dimopoulos
More informationOvercoming the PosESBLities of Enterobacteriaceae Resistance
Overcoming the PosESBLities of Enterobacteriaceae Resistance Review of current treatment options Jamie Reed, PharmD Pharmacy Grand Rounds August 28, 2018 Rochester, MN 2018 MFMER slide-1 Disclosure No
More informationFrequency of Occurrence and Antimicrobial Susceptibility of Bacteria from ICU Patients with Pneumonia
Frequency of Occurrence and Antimicrobial Susceptibility of Bacteria from ICU Patients with Pneumonia Helio S. Sader, M.D.* Mariana Castanheira, Ph.D. Rodrigo E. Mendes, Ph.D. Robert K. Flamm, Ph.D. JMI
More informationAcademic Perspective in. David Livermore Prof of Medical Microbiology, UEA Lead on Antibiotic resistance PHE
Academic Perspective in Emerging No, we can t Issues treat of carbapenemase Resistance and ESBL in Gram-ve producers Bacteria based on MIC David Livermore Prof of Medical Microbiology, UEA Lead on Antibiotic
More informationDetermining the Optimal Carbapenem MIC that Distinguishes Carbapenemase-Producing
AAC Accepted Manuscript Posted Online 8 August 2016 Antimicrob. Agents Chemother. doi:10.1128/aac.00838-16 Copyright 2016, American Society for Microbiology. All Rights Reserved. 1 1 2 Determining the
More informationAntibacterial Antibiotic Resistancein 2016 What Should an Internist Know? Disclosures. Objectives 3/6/2016. Achaogen: Allergan:
Antibacterial Antibiotic Resistancein 2016 What Should an Internist Know? Michael Satlin, MD, MS Assistant Professor of Medicine Division of Infectious Diseases Weill Cornell Medicine March 4, 2016 1 Disclosures
More informationExpert rules. for Gram-negatives
Academic Perspective in Expert rules Emerging Issues of Resistance in Gram-ve Bacteria for Gram-negatives Trevor Winstanley Sheffield Teaching Hospitals Presented on behalf of David Livermore University
More informationNew Antimicrobials: Now and In the Future
New Antimicrobials: Now and In the Future David C. Hooper, M.D. Division of Infectious Diseases Infection Control Unit Massachusetts General Hospital Harvard Medical School Conflicts of Interest Melinta
More informationNDA Briefing Document Anti-Infective Drugs Advisory Committee 05 December 2014
CEFTAZIDIME-AVIBACTAM FOR INJECTION for Treatment of Complicated Intra-abdominal Infection (used in combination with metronidazole), Complicated Urinary Tract Infection including Acute Pyelonephritis,
More informationResistance to Polymyxins in France
Resistance to Polymyxins in France Paris Prof. Patrice Nordmann NDM producers in Enterobacteriaceae The polymyxins; colistin and polymyxin B Colistin - Synthesis by Bacillus polymyxa spp colistinus -
More informationExpert rules in antimicrobial susceptibility testing: State of the art
Expert rules in antimicrobial susceptibility testing: State of the art ESCMID Postgraduate Education Course Antimicrobial Susceptibility Testing and Surveillance: from Laboratory to Clinic Hospital Universitario
More informationCarbapenem resistance has emerged worldwide in clinical isolates of Enterobacteriaceae. crossm
SUSCEPTIBILITY crossm In Vitro Activity of Meropenem-Vaborbactam against Clinical Isolates of KPC-Positive Enterobacteriaceae Meredith A. Hackel, a Olga Lomovskaya, b Michael N. Dudley, b James A. Karlowsky,
More informationTreatment Strategies for Infections due to MDR-GNR
Treatment Strategies for Infections due to MDR-GNR Michael Satlin, MD Instructor in Medicine Division of Infectious Diseases Weill Cornell Medical College, New York, NY October 16, 2012 1 2 Faculty Disclosure
More informationTP Larry Tsai, MD Chief Medical Officer Tetraphase Pharmaceuticals
TP-676 Larry Tsai, MD Chief Medical Officer Tetraphase Pharmaceuticals Tetraphase Pharmaceuticals Overview Tetraphase is developing novel antibiotics for serious and life-threatening Gram-negative MDR
More informationR EVIEWS OF T HERAPEUTICS
R EVIEWS OF T HERAPEUTICS Meropenem and Vaborbactam: Stepping up the Battle against Carbapenem-resistant Enterobacteriaceae Sarah Christina Jane Jorgensen, 1 and Michael Joseph Rybak 1,2,3, * 1 Anti-infective
More informationMHSAL Guidelines for the Prevention and Control of Antimicrobial Resistant Organisms (AROs) - Response to Questions
MHSAL Guidelines for the Prevention and Control of Antimicrobial Resistant Organisms (AROs) - Response to Questions Dr. Andrew Walkty Medical Microbiologist, Diagnostic Services Manitoba (DSM) June. 17,
More informationConsultation on the Revision of Carbapenem Breakpoints
Consultation on the Revision of Carbapenem Breakpoints July 2018 Please send comments to the EUCAST Scientific Secretary at jturnidge@gmail.com by September 15. EUCAST revision of carbapenem breakpoints
More informationUpdate on CLSI and EUCAST
Update on CLSI and EUCAST 1 Completed work» Cephalosporin breakpoints for Enterobacteriaceae ESBL screens MIC versus resistance mechanism» Carbapenem breakpoints for Enterobacteriaceae Modified Hodge Test»
More informationPresented at the annual meeting of the American Society of Microbiology, June 1-5, 2017, New Orleans, LA, USA
Is Associated With Improved Survival and Safety Compared to Colistin in Serious Carbapenemresistant Enterobacteriaceae (CRE) Infections: Results of the CARE Study Lynn E. Connolly 1, Adrian M. Jubb 1,
More informationDetecting CRE. what does one need to do?
5 th ICAN Conference, Harare 4 th November 2014 Room 2: 10:30-12:00 Detecting CRE (Carbapenem-resistant Enterobacteriaceae) what does one need to do? Dr Nizam Damani Associate Medical Director Infection
More informationCarbapenem-resistant Escherichia coli and Klebsiella pneumoniae in Taiwan
Carbapenem-resistant Escherichia coli and Klebsiella pneumoniae in Taiwan An Infection Control Emergency Speaker: L Kristopher Siu Principal Investigator Division of Infectious Diseases National Institute
More informationContinuous Infusion of Antibiotics In The ICU: What Is Proven? Professor of Medicine Vice-Chairman, Department of Medicine SUNY at Stony Brook
Continuous Infusion of Antibiotics In The ICU: What Is Proven? Michael S. Niederman, M.D. Chairman, Department of Medicine Winthrop-University Hospital Mineola, NY Professor of Medicine Vice-Chairman,
More informationGiving the Proper Dose: How Can The Clinical and Laboratory Standards Institute(CLSI)Help?
Giving the Proper Dose: How Can The Clinical and Laboratory Standards Institute(CLSI)Help? Pranita D. Tamma, M.D., M.H.S. Director, Pediatric Antimicrobial Stewardship Johns Hopkins University School of
More informationLa farmacologia in aiuto
Ferrara, 15 giugno 2018 La farmacologia in aiuto Pier Giorgio Cojutti, Federico Pea Istituto di Farmacologia Clinica Azienda Sanitaria Universitaria Integrata di Udine Therapeutic Drug Monitoring of Beta-Lactams
More informationβ-lactamase inhibitors
β-lactamase inhibitors Properties, microbiology & enzymology DAVID M LIVERMORE Professor of Medical Microbiology, UEA Lead on Antibiotic Resistance, Public Health England β-lactamase classes A B C D Serine
More informationDisclosure. Objectives. Evolution of β Lactamases. Extended Spectrum β Lactamases: The New Normal. Prevalence of ESBL Mystic Program
47 th Annual Meeting August 2-4, 2013 Orlando, FL Extended Spectrum β Lactamases: The New Normal Disclosure I do have a vested interest in or affiliation with the following companies or organizations Triax
More informationTreatment Options for Carbapenem-Resistant Enterobacteriaceae Infections
REVIEW ARTICLE Treatment Options for Carbapenem-Resistant Enterobacteriaceae Infections Haley J. Morrill, 1,2 Jason M. Pogue, 3 Keith S. Kaye, 4 and Kerry L. LaPlante 1,2,5 1 Veterans Affairs Medical Center,
More informationAAC Accepts, published online ahead of print on 13 October 2008 Antimicrob. Agents Chemother. doi: /aac
AAC Accepts, published online ahead of print on 13 October 2008 Antimicrob. Agents Chemother. doi:10.1128/aac.00931-08 Copyright 2008, American Society for Microbiology and/or the Listed Authors/Institutions.
More informationNew Mechanisms of Antimicrobial Resistance and Methods for Carbapenemase Detection
New Mechanisms of Antimicrobial Resistance and Methods for Carbapenemase Detection Stephen G. Jenkins, PhD, F(AAM), D(ABMM) Professor of Pathology and Laboratory Medicine Professor of Pathology in Medicine
More informationOptimizing Polymyxin Combinations Against Resistant Gram-Negative Bacteria
Infect Dis Ther (2015) 4:391 415 DOI 10.1007/s40121-015-0093-7 REVIEW Optimizing Polymyxin Combinations Against Resistant Gram-Negative Bacteria Phillip J. Bergen Zackery P. Bulman Cornelia B. Landersdorfer
More informationUse of imipenem. with the support of Wallonie-Bruxelles International. Magali Dodémont Microbiology Hospital Erasme Université Libre de Bruxelles
with the support of Wallonie-Bruxelles International Use of imipenem Magali Dodémont Microbiology Hospital Erasme Université Libre de Bruxelles 1 Β-lactams classification 2 Β-lactams: mode of action Inhibition
More informationCarbapenemases and new antibiotics
Carbapenemases and new antibiotics Youri Glupczynski, MD, PhD National Reference Centre for Antiotic Resistant Gram-Negative bacilli Laboratory of Clinical Microbiology, CHU UCL Namur (Mont-Godinne) De
More informationControversial Issues in Susceptibility Testing: Point/Counterpoint. April N. Abbott, PhD D(ABMM) Romney M. Humphries, PhD D(ABMM)
Controversial Issues in Susceptibility Testing: Point/Counterpoint April N. Abbott, PhD D(ABMM) Romney M. Humphries, PhD D(ABMM) Disclosures RMH: Funding from BD, biomerieux, Beckman-Coulter, GenMark,
More informationReceived 31 January 2011/Returned for modification 2 March 2011/Accepted 15 March 2011
JOURNAL OF CLINICAL MICROBIOLOGY, May 2011, p. 1965 1969 Vol. 49, No. 5 0095-1137/11/$12.00 doi:10.1128/jcm.00203-11 Copyright 2011, American Society for Microbiology. All Rights Reserved. Comparative
More informationPolymyxin B and Colistin Debate: One of the Same Kind or Mutt and Jeff?
Polymyxin B and Colistin Debate: One of the Same Kind or Mutt and Jeff? Bruce M. Jones, PharmD, BCPS Clinical Pharmacy Specialist Infectious Diseases St. Joseph's/Candler Health System, Inc. Clinical Adjunct
More informationLa batteriocidia sierica: passato e presente
Genova, 23 settembre 2016 La batteriocidia sierica: passato e presente Dott.ssa Maddalena Giannella Clinica di Malattie Infettive AOU Policlinico Sant Orsola Malpighi Case 1 Case 2 Summary: Cured of cancer
More informationThe CLSI Approach to Setting Breakpoints
The CLSI Approach to Setting Breakpoints Jean B. Patel, PhD, D(ABMM) Deputy Director, Office of Antimicrobial Resistance Division of Healthcare Quality Promotion National Center for Emerging and Zoonotic
More informationCarbapenems and Enterobacteriaceae
Title Carbapenems and Enterobacteriaceae Presenter s details NHLS Dr Khine Swe Swe/Han FC Path ( Micro), SA MMed( micro), SA DTMH(Wits univ),sa PDIC(Stellen univ)sa MB,BS(Yangon),Myanmar Pathologist,Consultant/Lecturer,
More informationEvaluation of the in vitro activity of ceftazidime-avibactam and ceftolozane-tazobactam
AAC Accepted Manuscript Posted Online 14 March 2016 Antimicrob. Agents Chemother. doi:10.1128/aac.02969-15 Copyright 2016, American Society for Microbiology. All Rights Reserved. 1 2 Evaluation of the
More informationNational Center for Emerging and Zoonotic Infectious Diseases The Biggest Antibiotic Resistance Threats
National Center for Emerging and Zoonotic Infectious Diseases The Biggest Antibiotic Resistance Threats Jean B. Patel, PhD, D(ABMM) Science Lead, Antibiotic Resistance and Coordination Unit Centers for
More information10/4/16. mcr-1. Emerging Resistance Updates. Objectives. National Center for Emerging and Zoonotic Infectious Diseases. Alex Kallen, MD, MPH, FACP
National Center for Emerging and Zoonotic Infectious Diseases Emerging Resistance Updates Alex Kallen, MD, MPH, FACP Lead Antimicrobial Resistance and Emerging Pathogens Team Prevention and Response Branch
More informationGuidance on screening and confirmation of carbapenem resistant Enterobacteriacae (CRE) December 12, 2011
Guidance on screening and confirmation of carbapenem resistant Enterobacteriacae (CRE) December 12, 2011 Objectives: To discuss the guidelines for detection of CRE in the laboratory setting. To review
More informationDiane M. Gomes, Pharm.D. Outcomes in Antimicrobial Stewardship Post-Doctoral Pharmacy Fellow Providence Veterans Affairs Medical Center
Diane M. Gomes, Pharm.D. Outcomes in Antimicrobial Stewardship Post-Doctoral Pharmacy Fellow Providence Veterans Affairs Medical Center The information disseminated in this lecture is given in my personal
More informationDiscussion points CLSI M100 S19 Update. #1 format of tables has changed. #2 non susceptible category
Discussion points 2009 CLSI M100 S19 Update Nebraska Public Health Laboratory Changes most important to routine antimicrobial susceptibility testing. Documents available Janet Hindler discussion slide
More informationHOW BUGS COMBAT DRUGS: ANTIMICROBIAL RESISTANCE MECHANISMS IN THE MODERN ERA. Romney Humphries, PhD D(ABMM)
HOW BUGS COMBAT DRUGS: ANTIMICROBIAL RESISTANCE MECHANISMS IN THE MODERN ERA Romney Humphries, PhD D(ABMM) Section Chief, UCLA Clinical Microbiology Los Angeles CA rhumphries@mednet.ucla.edu WHAT WE WILL
More informationClinical Management of Infections Caused by Enterobacteriaceae that Express Extended- Spectrum β-lactamase and AmpC Enzymes
56 Clinical Management of Infections Caused by Enterobacteriaceae that Express Extended- Spectrum β-lactamase and AmpC Enzymes Patrick N. A. Harris, BSc, MBBS, MRCP, DTM&H, FRACP, FRCPA 1 1 Infection and
More informationTerapia delle infezioni da Pseudomonas aeruginosa MDR
Verona 23 ottobre 2010 Terapia delle infezioni da Pseudomonas aeruginosa MDR Pierluigi Viale Clinica di Malattie Infettive Policlinico S. Orsola Malpighi Global resistance surveillance of Pseudomonas aeruginosa
More informationPlazomicin Versus Meropenem for the Treatment of Complicated Urinary Tract Infection and Acute Pyelonephritis: Results of the EPIC Study
Plazomicin Versus Meropenem for the Treatment of Complicated Urinary Tract Infection and Acute Pyelonephritis: Results of the EPIC Study Daniel J. Cloutier 1, Loren G. Miller 2, Allison S. Komirenko 1,
More informationPublic Health Surveillance for Multi Drug Resistant Organisms in Orange County
Public Health Surveillance for Multi Drug Resistant Organisms in Orange County Matt Zahn, MD Medical Director Epidemiology and Assessment Orange County Public Health Antimicrobial Mechanisms of Action
More informationESCMID Online Lecture Library. by author
www.eucast.org EXPERT RULES IN ANTIMICROBIAL SUSCEPTIBILITY TESTING Dr. Rafael Cantón Hospital Universitario Ramón y Cajal SERVICIO DE MICROBIOLOGÍA Y PARASITOLOGÍA Departamento de Microbiología II Universidad
More informationCefotaxime Rationale for the EUCAST clinical breakpoints, version th September 2010
Cefotaxime Rationale for the EUCAST clinical breakpoints, version 1.0 26 th September 2010 Foreword EUCAST The European Committee on Antimicrobial Susceptibility Testing (EUCAST) is organised by the European
More informationTreatment Options for Urinary Tract Infections Caused by Extended-Spectrum Β-Lactamase-Producing Escherichia coli and Klebsiella pneumoniae
Treatment Options for Urinary Tract Infections Caused by Extended-Spectrum Β-Lactamase-Producing Escherichia coli and Klebsiella pneumoniae medicine.missouri.edu/jahm/treatment-options-urinary-tract-infections-caused-extended-spectrum-β-lactamase-producingescherichia-coli-klebsiella-pneumoniae/
More information2/6/14. What s Hot in ID Objectives
What s Hot in ID 2014 James S. Lewis II, Pharm.D., FIDSA ID Clinical Pharmacy Coordinator Oregon Health and Science University Portland, OR Objectives Describe highlights of the Interscience Conference
More informationGlobal Epidemiology of Carbapenem- Resistant Enterobacteriaceae (CRE)
Global Epidemiology of Carbapenem- Resistant Enterobacteriaceae (CRE) Mitchell J. Schwaber, MD MSc Director, National Center for Infection Control Ministry of Health State of Israel November 27, 2012 1
More informationPhenotypic detection of ESBLs and carbapenemases
Phenotypic detection of ESBLs and carbapenemases Standardized susceptibility testing residential workshop 2016 Katie Hopkins PhD Clinical Scientist Antimicrobial Resistance and Healthcare Associated Infections
More informationCarbapenemases in Enterobacteriaceae: Prof P. Nordmann Bicêtre hospital, South-Paris Med School
Carbapenemases in Enterobacteriaceae: 2012 Prof P. Nordmann Bicêtre hospital, South-Paris Med School March 21, 2012 Trends in Molecular Medecine NDM IMP OXA-48 KPC VIM ALERT VI M KPC KPC NDM I MP OXA-
More informationHepatitis C Treatment and the Role of the Pharmacist
Infectious Diseases Odds and Ends: Focus on Developments in Hepatology and Gram-Negative Infections Lindsey Childs-Kean, PharmD, MPH, BCPS Clinical Assistant Professor University of Florida College of
More informationCefuroxime iv Rationale for the EUCAST clinical breakpoints, version th September 2010
Cefuroxime iv Rationale for the EUCAST clinical breakpoints, version 1.0 26 th September 2010 Foreword EUCAST The European Committee on Antimicrobial Susceptibility Testing (EUCAST) is organised by the
More informationST11 KPC-2 Klebsiella pneumoniae detected in Taiwan
AAC Accepts, published online ahead of print on 30 January 2012 Antimicrob. Agents Chemother. doi:10.1128/aac.05576-11 Copyright 2012, American Society for Microbiology. All Rights Reserved. 1 2 3 4 5
More informationOther β-lactam. A. Carbapenems:
A. Carbapenems: Other β-lactam Carbapenems are synthetic β-lactam antibiotics Differ in structure from the penicillins in that the sulfur atom of the thiazolidine ring. Imipenem, meropenem, doripenem,
More informationCARBAPENEMASE PRODUCING ENTEROBACTERIACEAE
CARBAPENEMASE PRODUCING ENTEROBACTERIACEAE Veroniek Saegeman Veroniek Saegeman UZLeuven Carbapenemase producing Enterobacteriaceae (CPE) Introduction on antibiotic resistance Classification of ß-lactamases
More informationBelow is an overview of the oral and poster presentations featuring cefiderocol and S at IDWeek 2017:
SHIONOGI TO HIGHLIGHT RESEARCH ON CEFIDEROCOL (S-649266), A SIDEROPHORE CEPHALOSPORIN, AND S-033188, A CAP-DEPENDENT ENDONUCLEASE INHIBITOR FOR TREATMENT OF INFLUENZA, AT IDWEEK 2017 OSAKA, Japan and FLORHAM
More informationInfection Control Strategies to Avoid Carbapenam Resistance in Hospitals. Victor Lim International Medical University Malaysia
Infection Control Strategies to Avoid Carbapenam Resistance in Hospitals Victor Lim International Medical University Malaysia Outline of Lecture 1. Carbapenam resistance 2. Epidemiology of carbapenam resistance
More informationReporting blood culture results to clinicians: MIC, resistance mechanisms, both?
Reporting blood culture results to clinicians: MIC, resistance mechanisms, both? Christian G. Giske, MD, PhD Senior Consultant Physician/Associate Professor Department of Clinical Microbiology Karolinska
More informationThe Challenge of MDR and XDR infections Friday 14th September, Barcelona Multi-drug and Extremely drug-resistant Pseudomonas aeruginosa
The Challenge of MDR and XDR infections Friday 14th September, Barcelona Multi-drug and Extremely drug-resistant Pseudomonas aeruginosa Juan P. Horcajada Service of Infectious Diseases Hospital del Mar,
More informationPlazomicin for complicated urinary tract infection
October 2016 Horizon Scanning Research & Intelligence Centre Plazomicin for complicated urinary tract infection NIHR HSRIC ID: 9787 Lay summary Serious infections caused by Gram-negative bacteria are becoming
More informationEUCAST Frequently Asked Questions. by author. Rafael Cantón Hospital Universitario Ramón y Cajal, Madrid, Spain EUCAST Clinical Data Coordinator
EUCAST Frequently Asked Questions Rafael Cantón Hospital Universitario Ramón y Cajal, Madrid, Spain EUCAST Clinical Data Coordinator Erika Matuschek EUCAST Development Laboratory, Växjö Sweden Monday 24
More informationDetecting carbapenemases in Enterobacteriaceae
Detecting carbapenemases in Enterobacteriaceae David Livermore Health Protection Agency, Colindale, London 12 August 2003 Mechanisms of carbapenem R in Enterobacteria Impermeability + AmpC or ESBL Metallo
More informationTranslocation Studies Mid-Term Review (MTR) Meeting Marseille, France
Marie Curie Actions Research Training Networks (RTN) Translocation Studies Mid-Term Review (MTR) Meeting Marseille, France F. Vidal-Aroca, M.G.P. Page and J. Dreier Background Deteriorating situation regarding
More informationPhenotypic Detection Methods of Carbapenemase Production in Enterobacteriaceae
ISSN: 2319-7706 Volume 4 Number 6 (2015) pp. 547-552 http://www.ijcmas.com Original Research Article Phenotypic Detection Methods of Carbapenemase Production in Enterobacteriaceae Sathya Pandurangan 1,
More informationDetection of Carbapenem Resistant Enterobacteriacae from Clinical Isolates
International Journal of Current Microbiology and Applied Sciences ISSN: 2319-7706 Volume 5 Number 5 (2016) pp. 864-869 Journal homepage: http://www.ijcmas.com Original Research Article http://dx.doi.org/10.20546/ijcmas.2016.505.089
More informationEmergence of non-kpc carbapenemases: NDM and more
Emergence of non-kpc carbapenemases: NDM and more --- David Livermore Health Protection Agency, UK The first acquired carbapenemase to be recognised in gram-negative bacteria was IMP-1, a metallo-type,
More informationRapid identification of emerging resistance in Gram negatives. Prof. Patrice Nordmann
Rapid identification of emerging resistance in Gram negatives Prof. Patrice Nordmann Emerging Resistance threats, CDC USA-2013 Enterobacteriaceae producing extendedspectrum β-lactamases (ESBL) Multi-resistant
More informationCompassionate use of cefiderocol as adjunctive treatment of native aortic valve endocarditis due to XDR-
Compassionate use of cefiderocol as adjunctive treatment of native aortic valve endocarditis due to XDR- Pseudomonas aeruginosa. Jonathan D Edgeworth 1, Domenico Merante 2, Sanjay Patel 2, Christopher
More informationNovel Approaches in the Management of C. difficile Infection. Stuart Johnson, MD
Novel Approaches in the Management of C. difficile Infection Stuart Johnson, MD Professor, Department of Medicine Stritch School of Medicine Loyola University Chicago, IL Overview Pathogenesis of CDI*
More information/01/$ DOI: /JCM Copyright 2001, American Society for Microbiology. All Rights Reserved.
JOURNAL OF CLINICAL MICROBIOLOGY, Jan. 2001, p. 183 190 Vol. 39, No. 1 0095-1137/01/$04.00 0 DOI: 10.1128/JCM.39.1.183 190.2001 Copyright 2001, American Society for Microbiology. All Rights Reserved. Contemporary
More informationIn-House Standardization of Carba NP Test for Carbapenemase Detection in Gram Negative Bacteria
International Journal of Current Microbiology and Applied Sciences ISSN: 2319-7706 Volume 7 Number 01 (2018) Journal homepage: http://www.ijcmas.com Original Research Article https://doi.org/10.20546/ijcmas.2018.701.342
More informationCarbapenem Disks on MacConkey agar as screening methods for the detection of. Carbapenem-Resistant Gram negative rods in stools.
JCM Accepts, published online ahead of print on 7 November 2012 J. Clin. Microbiol. doi:10.1128/jcm.02878-12 Copyright 2012, American Society for Microbiology. All Rights Reserved. 1 2 Carbapenem Disks
More informationScreening and detection of carbapenemases
Screening and detection of carbapenemases For many isolates with carbapenemases the MICs of carbapenems are around the susceptible breakpoint making resistance difficult to detect - particularly with automated
More informationAffinity of Doripenem and Comparators to Penicillin-Binding Proteins in Escherichia coli and ACCEPTED
AAC Accepts, published online ahead of print on February 00 Antimicrob. Agents Chemother. doi:./aac.01-0 Copyright 00, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights
More informationAntibiotics to treat multi-drug-resistant bacterial infections
Antibiotics to treat multi-drug-resistant bacterial infections July 2013 JUNE 2013 Copyright 2013 Tetraphase Pharmaceuticals, Inc. 1 Forward Looking Statements and Other Important Cautions Any statements
More informationScottish Microbiology and Virology Network. Carbapenemase producers: screening and the new Scottish AMR Satellite Reference Laboratory Service
Scottish Microbiology and Virology Network Carbapenemase producers: screening and the new Scottish AMR Satellite Reference Laboratory Service Total number of carbapenemase producing organisms isolated
More informationHOSPITAL EPIDEMOLOGY AND INFECTION CONTROL: STANDARD AND TRANSMISSION-BASED ISOLATION
Appendix 1: Carbapenem-Resistant Enterobacteriacaea (CRE) I. Definition: 2015 CDC definition of CRE are Enterobacteriaceae 1 that are: A. Resistant to any carbapenem antimicrobial (i.e., minimum inhibitory
More informationShaun Yang, PhD, D(ABMM), MLS(ASCP) CM MB CM Assistant Professor of Pathology UNM Health Sciences Center Associate Director of Infectious Disease
Shaun Yang, PhD, D(ABMM), MLS(ASCP) CM MB CM Assistant Professor of Pathology UNM Health Sciences Center Associate Director of Infectious Disease Director of Molecular Infectious Disease TriCore Reference
More informationIN VITRO ACTIVITY OF POLYMYXIN B AND MEROPENEM ALONE AND IN COMBINATION AGAINST CARBAPENEM- RESISTANT ENTEROBACTERIACEAE
University of Kentucky UKnowledge Theses and Dissertations--Pharmacy College of Pharmacy 2016 IN VITRO ACTIVITY OF POLYMYXIN B AND MEROPENEM ALONE AND IN COMBINATION AGAINST CARBAPENEM- RESISTANT ENTEROBACTERIACEAE
More informationRecommendations for the Management of Carbapenem- Resistant Enterobacteriaceae (CRE) in Acute and Long-term Acute Care Hospitals
Recommendations for the Management of Carbapenem- Resistant Enterobacteriaceae (CRE) in Acute and Long-term Acute Care Hospitals Minnesota Department of Health 11/2011 Infectious Disease Epidemiology,
More informationβ- Lactamase Gene carrying Klebsiella pneumoniae and its Clinical Implication
Prevalence of Carbapenem-Hydrolyzing β- Lactamase Gene carrying Klebsiella pneumoniae and its Clinical Implication David Alcid M.D Balaji Yegneswaran M.D. Wanpen Numsuwan Introduction Klebsiella pneumoniae
More informationSpread of carbapenems resistant Enterobacteriaceae in South Africa; report from National Antimicrobial Resistance Reference Laboratory
Spread of carbapenems resistant Enterobacteriaceae in South Africa; report from National Antimicrobial Resistance Reference Laboratory Olga Perovic*, Ashika Singh-Moodley, Samantha Iyaloo 5 th November
More informationComment l EUCAST fixe les concentrations critiques (Breakpoints), Associations inhibiteurs de ß-lactamases et ß-lactamines. Nouvelles molécules
Comment l EUCAST fixe les concentrations critiques (Breakpoints), Associations inhibiteurs de ß-lactamases et ß-lactamines Nouvelles molécules L. Dubreuil Maître de conférences en Pharmacologie Professeur
More informationShow Me the Money! Antimicrobials vs. Rapid Diagnostics. It s Friday at 4:00
Show Me the Money! Antimicrobials vs. Rapid Diagnostics Melissa D. Johnson, PharmD, MHS, AAHIVP Associate Professor of Medicine Clinical Liaison Pharmacist Duke Antimicrobial Outreach Network Duke University
More informationRapid identification and resistance assessment: The future is mass spectrometry
Rapid identification and resistance assessment: The future is mass spectrometry Dr Sanmarié Schlebusch Director of Microbiology Mater Pathology Brisbane Outline Introduction Plug and play Pre-prep and
More information